TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05454384

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.

Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
Study: NCT00688233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seifi's Functional
Description: Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
Study: NCT01550705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
Study: NCT01520142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26528398
Description: In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
Study: NCT01757912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cuff pressure
Description: The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
Study: NCT03936465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986378
Description: BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986378
Description: BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
Study: NCT00962364

Intervention type: BIOLOGICAL
Intervention: autologous bone marrow-derived cells
Description: autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia

Intervention type: BIOLOGICAL
Intervention: autologous bone marrow-derived cells
Description: autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia

Intervention type: BIOLOGICAL
Intervention: autologous bone marrow-derived cells
Description: autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
Study: NCT02493010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arousal-based biofeedback system
Study: NCT03136341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abobotulinum toxin A
Description: Dosing will be determined at each study visit based upon muscles involved

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be determined at each study visit based upon muscles involved
Study: NCT04558775

Intervention type: OTHER
Intervention: Observational
Description: no intervention
Study: NCT00880581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: 18 mg injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiotherapy
Description: 2 gray (2 Gy) on each of Days 1 and 2
Study: NCT02071862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pac-CB
Description: CB-839 in combination with standard dose paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBE
Description: CB-839 in combination with standard dose everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Erl
Description: CB-839 in combination with standard dose erlotnib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CB-839 in combination with standard dose docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Cabo
Description: CB-839 in combination with standard dose cabozantinib
Study: NCT02809105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: Oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily
Study: NCT01202370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-t-butyldimethylsilyl-10-hydroxycamptothecin
Description: IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
Study: NCT03544931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMD Application
Description: Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
Study: NCT01601327

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Testosterone enanthate (Sustanon 250 mg)
Description: Twenty-eight patients were treated with testosterone enanthate (TE),

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone enanthate (Sustanon 250 mg)
Description: Twenty-eight patients were treated with testosterone enanthate (TE),

Intervention type: DRUG
Group type: OTHER
Intervention: Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)
Description: twenty-five patients were treated with human chorionic gonadotropin (hCG)

Intervention type: DRUG
Group type: OTHER
Intervention: Testosteron gel (Testojel 50 mg)
Description: Twenty-four patients were treated with testosterone gel (TG).
Study: NCT03820219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena™ system
Description: The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard sterile wound dressing
Description: Standard wound care involves the application of an occlusive dressing in the operating room.
Study: NCT04653337

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
Study: NCT03465501

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy
Description: Brachytherapy
Study: NCT01185223

Intervention type: DRUG
Group type: OTHER
Intervention: Valganciclovir
Description: Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: 2x5mg/kg/d intravenous ganciclovir
Study: NCT01661933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus
Description: Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus
Description: After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
Study: NCT04234295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat Tissue Biopsy
Description: If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Tissue Biopsy
Description: If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
Study: NCT03775122

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TAES
Description: TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAES
Description: TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
Study: NCT01619644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with an oral dosage of 30 mg/kg/jour
Study: NCT00562289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: during the follow up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivitamins K or rivaroxaban or dabigatran or apixaban
Description: during the follow up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devices for PFO closure
Description: endovascular treatment no longer than 21 days after the random.
Study: NCT01952119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secure message reminder
Description: Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
Study: NCT02957058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAR technique
Description: Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAR technique
Description: Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
Study: NCT01993589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers during curattage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers during curattage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers during curattage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers during curattage
Study: NCT01764789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients will participate in a quality life assessment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Participate in multi-component biobehavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Participate in multi-component biobehavioral intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in multi-component biobehavioral intervention
Study: NCT02971436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake On + Pressure Support A
Description: FPH Device with SensAwake On + Pressure Support A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake Off + Pressure Support A
Description: FPH Device with SensAwake Off + Pressure Support A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake On + Pressure Support B
Description: FPH Device with SensAwake On + Pressure Support B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake Off + Pressure Support B
Description: FPH Device with SensAwake Off + Pressure Support B
Study: NCT01698658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound tomography
Description: Undergo ultrasound tomography using SoftVue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI of the breast
Study: NCT03459313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active group
Description: For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
Study: NCT04403802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voxx Human Performance Technology Socks
Description: Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming.
Study: NCT01202383

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Household-based water treatment with placebo tablets
Description: Study participants will be supplied with tablets and encouraged to use them for treating their water daily
Study: NCT00749671

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index monitoring
Description: The monitoring of the EEG signal is designed to determine if the sedation is adequate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramsey Sedation Scale
Description: The determination of the degree of sedation is accomplished using an established sedation scale.
Study: NCT02827799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Heart Failure Self-Management Education
Description: This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
Study: NCT04186884

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03282799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant
Description: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etonogestrel implant
Description: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
Study: NCT03501888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: 18 sessions of individual treatment, no manual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: 18 sessions of group treatment, manual based.
Study: NCT04438369

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Cathether based Erector Spinae Plane Block for postoperative pain management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Cathether based Erector Spinae Plane Block for postoperative pain management.